Global Gastrointestinal Therapeutics Market, Sector / Industry Report & Analysis 2018-2025 (Includes Business Impact of COVID-19)

                                          
Abstract, Snapshot, Market Analysis & Market Definition: Global Gastrointestinal Therapeutics Market


The global gastrointestinal therapeutics market size was valued at USD 51.9 billion in 2016 and is slated to expand at a lucrative CAGR of 6.6% over the forecast period. Increasing adoption of biologics for treatment of gastrointestinal diseases is the primary driver of the market. According to the Centers for Disease Control and Prevention (CDC), it is estimated that approximately 1-1.3 million people are suffering from Inflammatory Bowel Disease (IBD) in U.S. Prevalence of Crohn’s disease and ulcerative colitis is 201 per 100,000 adults and 238 per 100,000 adults, respectively.
 
A wide range of new generation therapeutics targets that include novel small molecules and cellular therapy are currently under investigation. These include tofacitinib, ustekinumab, mongersen, and vedolizumab. This influx is anticipated to be a consequence of high prevalence of gastrointestinal diseases globally. Vedolizumab is emerging as a first-line biologic therapy for Crohn’s disease. Currently, the U.S. FDA has approved Humira, Amjevita, Cimzia, Remicade, Renflexis, Inflectra, Tysabri, and Entyvio for the treatment of Crohn’s disease.
Some studies have indicated that biologics exhibit greater long-term efficiency. According to a study conducted by University of Chicago, usage of biologics has resulted in an overall decrease in the number of surgeries by approximately 40.0%, emergency room visits by 60.0%, and hospitalizations by 50.0%.
Similarly, the National Institute carried out a study on effectiveness of infliximab in treatment for Health Research and it was reported to be a cost-effective solution in episodic treatment of active Crohn’s Disease. Increasing need for cost containment in drug development as well as administration costs is likely to fuel growth opportunities for biologics. Advent of targeted treatment alternatives has led to development of more personalized biologics.

Market Segmentation, Outlook & Viewpoint: Global Gastrointestinal Therapeutics Market


Type Market Segmentation & Outlook (Revenue, USD Million, 2014 - 2025)

Branded

Aminosalicylates

Antacids

Enzyme Replacement Therapies

Proton-pump Inhibitors

Laxatives

Antiemetics

H2 Antagonists

Antidiarrheals

Biologics

Others


Generics


Route of Administration Market Segmentation & Outlook (Revenue, USD Million, 2014 - 2025)

Oral

Intravenous

Others


Application Market Segmentation & Outlook (Revenue, USD Million, 2014 - 2025)

Ulcerative Colitis

Crohn’s Disease

GERD

Others


Distribution Channel Market Segmentation & Outlook (Revenue, USD Million, 2014 - 2025)

Hospital Pharmacies

Retail Pharmacies

Online Pharmacies


Key Players, Recent Developments & Regional Insights: Global Gastrointestinal Therapeutics Market


The others segment accounted for the largest share by application in 2016. This segment includes opioid-induced constipation, chronic idiopathic constipation, diarrhea, recurrent gastrointestinal infections, nausea, gastrointestinal stromal tumor, pancreatic insufficiency, and irritable bowel syndrome. The substantial share can be attributed to a wide range of applications for which gastrointestinal drugs have been used consistently over the previous years. Frequent number of drug launches is also responsible for increased scope for growth.
Ulcerative colitis accounted for the second-largest share in the gastrointestinal therapeutics market in 2016. Growth of this segment can be attributed to easy availability of drugs to treat this condition. The segment is also anticipated to grow at a considerable rate owing to high clinical urgency to curb growing prevalence of ulcerative colitis. This high prevalence is due to poor prognosis and consumption of unhealthy food, which may result in high probability of disease recurrence.
The Crohn’s disease segment is anticipated to witness a lucrative growth rate throughout the forecast period. Rising prevalence of lifestyle-induced conditions such as excessive drinking and high incidence of chronic diseases such as cancer and diabetes, are major growth-rendering drivers. According to the CDC, approximately 1.0-1.3 million people are suffering from Inflammatory Bowel Disease (IBD). In U.S., prevalence of Crohn’s disease is 201 per 100,000 adults.
Distribution Channel Insights
In 2016, retail pharmacy accounted for the dominant share in terms of distribution channel owing to high affordability and accessibility to retail stores. As number of prescription medicines being reimbursed is increasing, it is encouraging patients to purchase medicines from retail pharmacies. Retail pharmacists also recommend drug substitutes that prevent adverse drug interactions.
These factors are likely to boost customer inclination toward retail stores. In case retail pharmacists have any concerns regarding prescribed medicines, they recommend alternatives for the same, thus ensuring higher safety. Advent of pharmacy chains such as CVS Health is a major contributor to the share of the retail segment. Adoption of digitalized systems in retail pharmacies to reduce risk of errors in prescriptions is also anticipated to fuel growth over the coming years.
 
Online pharmacies are expected to exhibit lucrative growth during the forecast period. This growth is anticipated to be a consequence of associated benefits such as high convenience for bed-ridden patients who find it difficult to purchase medicines from hospitals or retail stores. In addition, growing incidence of chronic diseases has resulted in a wide gap in the supply of and demand for major drugs. The aforementioned factors are expected to present remunerative growth prospects for online pharmacies during the forecast period.
With the advent of online pharmacies, tracking and order procurement have become convenient. Supply Chain Management (SCM) in online pharmacies enables integration of various market intermediaries of the delivery channel, which reduces overall cost, thereby further driving demand for this segment.

Regional Insights
The North America market accounted for the largest share in 2016 and is expected to maintain its position during the forecast period. This substantial share can be attributed to unprecedented change in lifestyle, resulting in greater incidence of gastrointestinal diseases.
Moreover, presence of government initiatives aimed at preventing as well as treating gastrointestinal diseases is expected to drive the market. For instance, the Integrated Global Action Plan for Diarrhoea by UNICEF and WHO aims at minimizing preventable childhood deaths as a result of diarrhea by providing interventions and services to raise awareness and provide access to treatment and preventive measures.
Asia Pacific is anticipated to exhibit exponential growth throughout the forecast period. This is likely to be fueled by consistent efforts undertaken by key players, which include R&D investments as well as commercialization of branded drugs at a relatively lower price. In addition, urgent need to curb high incidence rate of gastrointestinal disorders and technological upgradation of healthcare infrastructure are predicted to present the regional market with high potential growth opportunities over the forecast period.
Gastrointestinal Therapeutics Market Share Insights
Some of the key players in the market are Takeda Pharmaceuticals, Valeant Pharmaceuticals, Allergan plc, and Bayer AG. These key players have extensively employed competition sustainability strategies such as new product development and regional and distribution channel expansion to gain a higher share in the market. Moreover, increased focus on refining operation and supply chain management has facilitated key players to maintain a competitive edge.
For instance, in October 2016, Allergan plc completed a divesture of its generics business by selling Anda, Inc. to Teva Pharmaceuticals Industries Ltd. This divesture was carried out to increase the company’s focus on branded pharmaceuticals and expand key therapeutics areas. Similarly, in January 2016, Takeda Pharmaceuticals entered into strategic collaboration with Cour Pharmaceutical Development to develop advanced therapeutics for a wide range of gastrointestinal diseases.

Key Insights Covered: Global Gastrointestinal Therapeutics Market
1.  North America, Europe, Asia Pacific, Middle East & Africa, Latin America market size (sales, revenue and growth rate) of Gastrointestinal Therapeutics industry.
2. Global major manufacturers' operating situation (sales, revenue, growth rate and gross margin) of Gastrointestinal Therapeutics industry.
3. Global major countries (United States, Canada, Germany, France, UK, Italy, Russia, Spain, China, Japan, Korea, India, Australia, New Zealand, Southeast Asia, Middle East, Africa, Mexico, Brazil, C. America, Chile, Peru, Colombia) market size (sales, revenue and growth rate) of Gastrointestinal Therapeutics industry.
4. SWOT analysis, New Project Investment Feasibility Analysis, Upstream raw materials and manufacturing equipment & Industry chain analysis of Gastrointestinal Therapeutics industry.
5. Global market size (sales, revenue) forecast by regions and countries from 2019 to 2024 of Gastrointestinal Therapeutics industry.

Research Methodology: Global Gastrointestinal Therapeutics Market

Data collection and base year analysis is done using data collection modules with large sample sizes. The market data is analyzed and forecasted using market statistical and coherent models. Also market share analysis and key trend analysis are the major success factors in the market report. To know more please Request a Sample Report.
Demand Side Primary Contributors: OEMs, Industrial Professionals, Researches, Suppliers and Distributors, Group Purchasing Organizations, Associations, Insurers, Universities, Technological Writers, Scientists, Promoters, Investors among others.
Supply Side Primary Contributors: Product Managers, Marketing Managers, C-Level Executives, Distributors, Market Intelligence, Regulatory Affairs Managers among other